Efficacy of Tralokinumab in a Patient with Atopic Dermatitis Experiencing Loss of Response to Dupilumab: A Case Report
SKIN The Journal of Cutaneous Medicine · 10.11.2026 · 10 (6) · 3539-3542
DOI: 10.25251/rdbfq523 ↗Kurz gefasst
Fallbericht in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 10.11.2026. Verfasst von Amy McDowell und 5 weiteren Autor:innen. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Atopic dermatitis (AD) is driven by a self-perpetuating cycle of immune dysregulation and skin barrier dysfunction. While dupilumab provides sustained efficacy for moderate-to-severe disease, a subgroup of patients may experience a secondary loss of response, creating a therapeutic challenge due to limited real-world data. We present a 36-year-old male with severe upper-body AD (initial BSA 15%, pruritus 7/10) who achieved rapid clearance on dupilumab, maintaining a stable response for three years before experiencing a breakthrough flare (BSA 5%, pruritus 6/10). The adjunct introduction of delgocitinib cream, used to treat chronic hand eczema (CHE), alongside increased dupilumab frequency to weekly dosing yielded only partial clearance (BSA 2%, pruritus 6/10). Due to incomplete resolution, the patient transitioned to tralokinumab, an IL-13 inhibitor. After 12 weeks, the patient achieved complete clearance (BSA 0%, pruritus 0/10). This clinical case demonstrates that managing a secondary biologic failure does not necessitate a disruptive class switch to oral JAK inhibitors, IL-31 inhibitors, or traditional systemic immunosuppressants; rather, staying in class with a more targeted IL-13 inhibitor remains a highly effective strategy.
Zitieren
APA
McDowell, A., Daabies, O., O’Campo, J., Surman, N., Andrade, L. R., & Trickett, C. (2026). Efficacy of Tralokinumab in a Patient with Atopic Dermatitis Experiencing Loss of Response to Dupilumab: A Case Report. SKIN The Journal of Cutaneous Medicine, 10(6), 3539-3542. https://doi.org/10.25251/rdbfq523
Vancouver
McDowell A, Daabies O, O’Campo J, Surman N, Andrade LR, Trickett C. Efficacy of Tralokinumab in a Patient with Atopic Dermatitis Experiencing Loss of Response to Dupilumab: A Case Report. SKIN The Journal of Cutaneous Medicine. 2026;10(6):3539-3542. doi:10.25251/rdbfq523
BibTeX
@article{McDowell2026,
author = {McDowell, Amy and Daabies, Omar and O’Campo, Joanna and Surman, Nicole and Andrade, Lindsey Rae and Trickett, Cynthia},
title = {Efficacy of Tralokinumab in a Patient with Atopic Dermatitis Experiencing Loss of Response to Dupilumab: A Case Report},
journal = {SKIN The Journal of Cutaneous Medicine},
year = {2026},
volume = {10},
number = {6},
pages = {3539--3542},
doi = {10.25251/rdbfq523}
}
EUVIMED